News 'Dismal' survival demands change in bile duct cancer therapy International cancer experts have called for big changes to bile duct cancer, which kills three-quarters of patients within a year of diagnosis.
Market Access NICE and orphan drug recommendations: Should we be more worr... Leela Barham uses the very latest data – running up to November 2023 – to take stock of NICE’s Single Technology Appraisal (STA) recommendations on orphan drugs versus non-orphans.
News AstraZeneca adds another Chinese asset, from Dizal AstraZeneca has continued its pipeline-boosting deal spree in China with a $1.5bn licensing deal for Dizal Pharma's lung cancer therapy Zegfrovy.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.